NASDAQ:AQXP - Aquinox Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.56 -0.18 (-1.41 %)
(As of 05/25/2018 03:21 AM ET)
Previous Close$12.56
Today's Range$12.51 - $12.7599
52-Week Range$10.02 - $16.90
Volume36,627 shs
Average Volume101,304 shs
Market Capitalization$290.80 million
P/E Ratio-5.87
Dividend YieldN/A
Beta-14.25

About Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive AQXP News and Ratings via Email

Sign-up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AQXP
CUSIPN/A
Phone604-629-9223

Debt

Debt-to-Equity RatioN/A
Current Ratio10.08
Quick Ratio10.08

Price-To-Earnings

Trailing P/E Ratio-5.87
Forward P/E Ratio-5.53
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.65 per share
Price / Book3.44

Profitability

EPS (Most Recent Fiscal Year)($2.14)
Net Income$-50,180,000.00
Net MarginsN/A
Return on Equity-53.37%
Return on Assets-49.03%

Miscellaneous

Employees51
Outstanding Shares23,510,000

Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals (NASDAQ:AQXP) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.08. View Aquinox Pharmaceuticals' Earnings History.

When is Aquinox Pharmaceuticals' next earnings date?

Aquinox Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Aquinox Pharmaceuticals.

What price target have analysts set for AQXP?

4 brokers have issued twelve-month price targets for Aquinox Pharmaceuticals' shares. Their forecasts range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' stock price to reach $25.25 in the next twelve months. View Analyst Ratings for Aquinox Pharmaceuticals.

What are Wall Street analysts saying about Aquinox Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (5/15/2018)
  • 2. Needham & Company LLC analysts commented, "Aquinox reported 1Q18 financial results today and we spoke with mgmt for an update. The rosiptor Phase 3 LEADERSHIP trial in Interstitial Cystitis (IC)/ Bladder Pain Syndrome (BPS) remains on track for top-line results in 3Q18, most likely in July. 12wk trial was completed in Feb 2018. We expect a positive outcome based on Phase 2 data. Mgmt plans to revisit Phase 3 design w/ FDA prior to initiation of a planned second Phase 3 trial, which we believe may begin around YE18. Patient screening in a Phase 2 trial of rosiptor in Chronic Prostatitis (CP/ CPPS) is underway. Reiterate BUY. We do not believe the stock adequately reflects value of rosiptor program in BPS/IC." (5/8/2018)
  • 3. Cantor Fitzgerald analysts commented, "R&D day provided contemporary thoughts about IC/BPS and how rosiptor could address an unmet need. We attended an R&D day hosted by AQXP in NYC on Friday, Feb. 9 (presentation here). The company included Dr. Phillip Hanno (Clinical Prof, Stanford U.) on the program to provide a KOL viewpoint of interstitial cystitis/bladder pain syndrome (IC/BPS) and the treatment of it." (2/11/2018)
  • 4. Canaccord Genuity analysts commented, "We recently hosted a call with Dr. J. Quentin Clemens, chief of the Division of Neurourology and Pelvic Reconstruction, urology director for female pelvic medicine and professor of urology at the University of Michigan. While Dr. Clemens has not used AQXP’s rosiptor (AQX-1125), his discussion of IC/BPS provided us with more confidence in the design of the ongoing, pivotal Ph3 LEADERSHIP 301 assessing rosiptor in IC/BPS patients, which remains on track to complete enrollment in 1Q18 and for top-line data in 3Q18. We reiterate our BUY rating." (12/19/2017)

Who are some of Aquinox Pharmaceuticals' key competitors?

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the folowing people:
  • Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 53)
  • Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 44)
  • Ms. Abigail L. Jenkins, Chief Commercial Officer and U.S. Bus. Head (Age 42)
  • Mr. Lloyd Mackenzie, COO & VP of R&D Operations (Age 51)
  • Ms. Shelley McCloskey, VP of HR & Admin. (Age 58)

Has Aquinox Pharmaceuticals been receiving favorable news coverage?

News stories about AQXP stock have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.26 on Accern's scale. They also gave media headlines about the company an impact score of 45.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Aquinox Pharmaceuticals' major shareholders?

Aquinox Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (5.72%), BlackRock Inc. (3.41%), Point72 Asset Management L.P. (1.06%), University of Notre Dame DU Lac (0.59%), DAFNA Capital Management LLC (0.46%) and Dimensional Fund Advisors LP (0.31%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel J Levitt, David Main and Lloyd Mackenzie. View Institutional Ownership Trends for Aquinox Pharmaceuticals.

Which major investors are selling Aquinox Pharmaceuticals stock?

AQXP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., University of Notre Dame DU Lac, Point72 Asset Management L.P. and DAFNA Capital Management LLC. Company insiders that have sold Aquinox Pharmaceuticals company stock in the last year include Daniel J Levitt, David Main and Lloyd Mackenzie. View Insider Buying and Selling for Aquinox Pharmaceuticals.

Which major investors are buying Aquinox Pharmaceuticals stock?

AQXP stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Eversept Partners LLC, Franklin Resources Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Aquinox Pharmaceuticals.

How do I buy shares of Aquinox Pharmaceuticals?

Shares of AQXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquinox Pharmaceuticals' stock price today?

One share of AQXP stock can currently be purchased for approximately $12.56.

How big of a company is Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals has a market capitalization of $290.80 million. The company earns $-50,180,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Aquinox Pharmaceuticals employs 51 workers across the globe.

How can I contact Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]


MarketBeat Community Rating for Aquinox Pharmaceuticals (AQXP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  329
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aquinox Pharmaceuticals (NASDAQ:AQXP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Aquinox Pharmaceuticals in the last 12 months. Their average twelve-month price target is $25.25, suggesting that the stock has a possible upside of 101.04%. The high price target for AQXP is $28.00 and the low price target for AQXP is $22.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.25$25.25$25.25$25.00
Price Target Upside: 101.04% upside64.92% upside64.92% upside136.52% upside

Aquinox Pharmaceuticals (NASDAQ:AQXP) Consensus Price Target History

Price Target History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals (NASDAQ:AQXP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Needham & Company LLCReiterated RatingBuy$25.00HighView Rating Details
2/11/2018Cantor FitzgeraldReiterated RatingBuy$28.00MediumView Rating Details
2/8/2018GuggenheimInitiated CoverageBuy ➝ Buy$26.00HighView Rating Details
12/19/2017Canaccord GenuitySet Price TargetBuy$22.00LowView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$24.00N/AView Rating Details
8/5/2016Jefferies GroupBoost Price TargetHold$7.00 ➝ $9.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Aquinox Pharmaceuticals (NASDAQ:AQXP) Earnings History and Estimates Chart

Earnings by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals (NASDAQ:AQXP) Earnings Estimates

2018 EPS Consensus Estimate: ($2.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.68)($0.68)($0.68)
Q2 20181($0.71)($0.71)($0.71)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.55)($0.55)($0.55)

Aquinox Pharmaceuticals (NASDAQ AQXP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.63)N/AView Earnings Details
5/8/2018Q1($0.70)($0.62)ViewN/AView Earnings Details
3/12/2018After Market($0.59)($0.69)ViewListenView Earnings Details
11/8/2017Q3 2017($0.62)($0.50)ViewN/AView Earnings Details
8/8/20176/30/2017($0.59)($0.59)ViewListenView Earnings Details
5/9/20173/31/2017($0.51)($0.36)ViewN/AView Earnings Details
3/9/201712/31/2016($0.51)($0.48)ViewListenView Earnings Details
11/9/2016Q316($0.58)($0.46)ViewN/AView Earnings Details
8/4/2016Q2($0.41)($0.63)ViewN/AView Earnings Details
5/10/2016Q1($0.35)($0.39)ViewN/AView Earnings Details
3/14/2016Q4 2015($0.38)($0.27)ViewN/AView Earnings Details
11/10/2015Q315($0.45)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.56)($0.44)ViewN/AView Earnings Details
5/12/2015Q115($0.83)($0.60)ViewN/AView Earnings Details
4/15/2015($0.57)($0.78)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.76)($0.78)ViewN/AView Earnings Details
11/4/2014Q3 2014($0.29)($0.59)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.27)($0.51)ViewN/AView Earnings Details
5/13/2014Q1 2014($1.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aquinox Pharmaceuticals (NASDAQ:AQXP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aquinox Pharmaceuticals (NASDAQ AQXP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 90.05%
Insider Trading History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals (NASDAQ AQXP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018Daniel J LevittDirectorSell3,906$12.67$49,489.023,906View SEC Filing  
3/15/2018Lloyd MackenzieCOOSell1,302$14.63$19,048.261,302View SEC Filing  
6/5/2017David MainInsiderSell15,625$13.26$207,187.5077,530View SEC Filing  
1/9/2017Bros. Advisors Lp BakerMajor ShareholderBuy398,062$17.18$6,838,705.16View SEC Filing  
9/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy2,783,605$12.25$34,099,161.25View SEC Filing  
3/16/2016Bros. Advisors Lp BakerMajor ShareholderBuy471,667$7.99$3,768,619.33View SEC Filing  
3/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy109,912$7.98$877,097.76View SEC Filing  
1/26/2016Bros. Advisors Lp BakerMajor ShareholderBuy140,786$10.80$1,520,488.80View SEC Filing  
1/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy112,034$9.48$1,062,082.32View SEC Filing  
1/19/2016Bros. Advisors Lp BakerMajor ShareholderBuy78,045$9.11$710,989.95View SEC Filing  
1/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy202,623$8.28$1,677,718.44View SEC Filing  
9/10/2015Bros. Advisors Lp BakerMajor ShareholderBuy2,480,032$15.50$38,440,496.00View SEC Filing  
8/24/2015David Chilton MitchellVPBuy3,575$17.81$63,670.751,600View SEC Filing  
8/12/2015Kamran AlamCFOSell29,079$18.67$542,904.93View SEC Filing  
8/12/2015Lloyd MackenzieVPSell35,887$18.67$670,010.29View SEC Filing  
12/17/2014& Johnson JohnsonMajor ShareholderSell8,100$7.62$61,722.00View SEC Filing  
12/12/2014& Johnson JohnsonMajor ShareholderSell5,000$7.51$37,550.00View SEC Filing  
12/10/2014& Johnson JohnsonMajor ShareholderSell8,300$7.72$64,076.00View SEC Filing  
12/9/2014& Johnson JohnsonMajor ShareholderSell5,000$7.73$38,650.00View SEC Filing  
12/8/2014& Johnson JohnsonMajor ShareholderSell2,000$7.69$15,380.00View SEC Filing  
12/5/2014& Johnson JohnsonMajor ShareholderSell15,900$7.76$123,384.00View SEC Filing  
12/1/2014& Johnson JohnsonMajor ShareholderSell1,200$7.54$9,048.00View SEC Filing  
11/26/2014& Johnson JohnsonMajor ShareholderSell2,000$7.75$15,500.00View SEC Filing  
11/24/2014& Johnson JohnsonMajor ShareholderSell9,500$8.14$77,330.00View SEC Filing  
3/12/2014Pfizer IncMajor ShareholderBuy272,727$11.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aquinox Pharmaceuticals (NASDAQ AQXP) News Headlines

Source:
DateHeadline
Aquinox Pharmaceuticals (AQXP) Given Average Rating of "Buy" by AnalystsAquinox Pharmaceuticals (AQXP) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 24 at 1:47 PM
FY2018 Earnings Forecast for Aquinox Pharmaceuticals (AQXP) Issued By Cantor FitzgeraldFY2018 Earnings Forecast for Aquinox Pharmaceuticals (AQXP) Issued By Cantor Fitzgerald
www.americanbankingnews.com - May 24 at 8:50 AM
Aquinox Pharmaceuticals (AQXP) Director Sells $49,489.02 in StockAquinox Pharmaceuticals (AQXP) Director Sells $49,489.02 in Stock
www.americanbankingnews.com - May 16 at 10:28 PM
Aquinox to Present at 2018 UBS Global Healthcare ConferenceAquinox to Present at 2018 UBS Global Healthcare Conference
finance.yahoo.com - May 16 at 5:42 PM
Aquinox Pharmaceuticals (AQXP) Rating Increased to Hold at Zacks Investment ResearchAquinox Pharmaceuticals (AQXP) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 5:23 PM
Aquinox Pharmaceuticals (AQXP) Posts Quarterly  Earnings Results, Beats Expectations By $0.08 EPSAquinox Pharmaceuticals (AQXP) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 9 at 3:35 PM
Aquinox Pharmaceuticals (AQXP) Earns Buy Rating from Needham & Company LLCAquinox Pharmaceuticals (AQXP) Earns Buy Rating from Needham & Company LLC
www.americanbankingnews.com - May 8 at 9:16 PM
Aquinox: 1Q Earnings SnapshotAquinox: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:39 PM
Aquinox Pharmaceuticals Announces First Quarter 2018 Financial ResultsAquinox Pharmaceuticals Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 5:39 PM
How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?How Do Analysts See Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Performing Over The Next Few Years?
finance.yahoo.com - May 7 at 5:38 PM
Aquinox Pharmaceuticals (AQXP) Presents At 2018 Bloom Burton & Co. Healthcare Investor Conference - SlideshowAquinox Pharmaceuticals (AQXP) Presents At 2018 Bloom Burton & Co. Healthcare Investor Conference - Slideshow
seekingalpha.com - May 4 at 5:34 PM
Aquinox Pharmaceuticals (AQXP) Stock Rating Upgraded by BidaskClubAquinox Pharmaceuticals (AQXP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 3 at 11:50 AM
Aquinox to Present at Deutsche Bank 43rd Annual Healthcare ConferenceAquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference
finance.yahoo.com - May 2 at 5:36 PM
Aquinox Pharmaceuticals (AQXP) Scheduled to Post Quarterly Earnings on MondayAquinox Pharmaceuticals (AQXP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 9:22 AM
Aquinox Pharmaceuticals (AQXP) Given Consensus Recommendation of "Hold" by AnalystsAquinox Pharmaceuticals (AQXP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 29 at 1:36 PM
Aquinox to Present at 2018 Bloom Burton & Co. Healthcare ConferenceAquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference
finance.yahoo.com - April 26 at 5:17 PM
Aquinox Pharmaceuticals (AQXP) Given a $22.00 Price Target by Canaccord Genuity AnalystsAquinox Pharmaceuticals (AQXP) Given a $22.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 12 at 11:27 AM
Aquinox Pharmaceuticals (AQXP) Lowered to "Sell" at BidaskClubAquinox Pharmaceuticals (AQXP) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - April 10 at 11:28 AM
Aquinox Pharmaceuticals Inc (AQXP) Given Average Recommendation of "Hold" by BrokeragesAquinox Pharmaceuticals Inc (AQXP) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 1:47 PM
ValuEngine Upgrades Aquinox Pharmaceuticals (AQXP) to HoldValuEngine Upgrades Aquinox Pharmaceuticals (AQXP) to Hold
www.americanbankingnews.com - April 3 at 7:35 PM
Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%
finance.yahoo.com - March 26 at 8:22 AM
Aquinox Pharmaceuticals (AQXP) Upgraded to "Sell" by BidaskClubAquinox Pharmaceuticals (AQXP) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 25 at 3:47 PM
Aquinox to Present at the 17th Annual Needham Healthcare ConferenceAquinox to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 5:38 PM
Aquinox Pharmaceuticals Inc (AQXP) COO Sells $19,048.26 in StockAquinox Pharmaceuticals Inc (AQXP) COO Sells $19,048.26 in Stock
www.americanbankingnews.com - March 19 at 8:30 PM
Aquinox Pharmaceuticals (AQXP) Stock Rating Lowered by Zacks Investment ResearchAquinox Pharmaceuticals (AQXP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 16 at 5:06 PM
Aquinox Pharmaceuticals Inc to Post FY2018 Earnings of ($2.27) Per Share, Cantor Fitzgerald Forecasts (AQXP)Aquinox Pharmaceuticals Inc to Post FY2018 Earnings of ($2.27) Per Share, Cantor Fitzgerald Forecasts (AQXP)
www.americanbankingnews.com - March 16 at 10:42 AM
Aquinox Pharmaceuticals Inc (AQXP) to Post FY2019 Earnings of ($1.59) Per Share, Cantor Fitzgerald ForecastsAquinox Pharmaceuticals Inc (AQXP) to Post FY2019 Earnings of ($1.59) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 15 at 12:58 PM
Aquinox Pharmaceuticals Announces Year End 2017 Financial Results - GlobeNewswire (press release)Aquinox Pharmaceuticals Announces Year End 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:31 AM
Aquinox Pharmaceuticals (AQXP) Issues  Earnings ResultsAquinox Pharmaceuticals (AQXP) Issues Earnings Results
www.americanbankingnews.com - March 13 at 10:20 AM
Cantor Fitzgerald Remains Bullish on Aquinox Pharma (AQXP) Following 4Q - StreetInsider.comCantor Fitzgerald Remains Bullish on Aquinox Pharma (AQXP) Following 4Q - StreetInsider.com
www.streetinsider.com - March 13 at 8:25 AM
BRIEF-Aquinox Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250 Million - SEC FilingBRIEF-Aquinox Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing
www.reuters.com - March 12 at 6:40 PM
Aquinox Pharmaceuticals Announces Year End 2017 Financial ResultsAquinox Pharmaceuticals Announces Year End 2017 Financial Results
finance.yahoo.com - March 12 at 6:40 PM
Aquinox Pharmaceuticals, Inc. to Host Earnings CallAquinox Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 12 at 6:40 PM
Aquinox reports 4Q lossAquinox reports 4Q loss
finance.yahoo.com - March 12 at 6:40 PM
Morning News Call - Canada, March 12Morning News Call - Canada, March 12
finance.yahoo.com - March 12 at 9:01 AM
Aquinox Pharmaceuticals Inc (AQXP) Given Average Rating of "Hold" by AnalystsAquinox Pharmaceuticals Inc (AQXP) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 10 at 1:53 PM
Aquinox Pharmaceuticals Inc (AQXP) Shares Bought by Emory UniversityAquinox Pharmaceuticals Inc (AQXP) Shares Bought by Emory University
www.americanbankingnews.com - March 4 at 2:59 PM
Aquinox Pharmaceuticals (AQXP) to Release Quarterly Earnings on WednesdayAquinox Pharmaceuticals (AQXP) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM
Zacks: Brokerages Expect Aquinox Pharmaceuticals Inc (AQXP) to Post -$0.65 Earnings Per ShareZacks: Brokerages Expect Aquinox Pharmaceuticals Inc (AQXP) to Post -$0.65 Earnings Per Share
www.americanbankingnews.com - February 19 at 5:16 PM
Aquinox Pharmaceuticals (AQXP) Lifted to Hold at BidaskClubAquinox Pharmaceuticals (AQXP) Lifted to Hold at BidaskClub
www.americanbankingnews.com - February 18 at 3:32 PM
Aquinox Pharma (AQXP) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowAquinox Pharma (AQXP) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:18 PM
Analyzing Eli Lilly and (LLY) and Aquinox Pharmaceuticals (AQXP)Analyzing Eli Lilly and (LLY) and Aquinox Pharmaceuticals (AQXP)
www.americanbankingnews.com - February 16 at 1:18 AM
Aquinox Pharmaceuticals (AQXP) Buy Rating Reiterated at Cantor FitzgeraldAquinox Pharmaceuticals' (AQXP) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - February 12 at 12:32 AM
Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of RosiptorAquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor
finance.yahoo.com - February 9 at 9:49 AM
Aquinox Pharmaceuticals (AQXP) Earns Buy Rating from Analysts at GuggenheimAquinox Pharmaceuticals (AQXP) Earns Buy Rating from Analysts at Guggenheim
www.americanbankingnews.com - February 8 at 8:54 PM
Zacks: Brokerages Anticipate Aquinox Pharmaceuticals Inc (AQXP) Will Announce Earnings of -$0.65 Per ShareZacks: Brokerages Anticipate Aquinox Pharmaceuticals Inc (AQXP) Will Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - February 2 at 5:10 PM
Cara Therapeutics’ Collaboration AgreementsCara Therapeutics’ Collaboration Agreements
finance.yahoo.com - February 2 at 9:19 AM
Comparing Cara Therapeutics’ Financial PerformanceComparing Cara Therapeutics’ Financial Performance
finance.yahoo.com - February 2 at 9:19 AM
Aquinox Pharmaceuticals (AQXP) versus Celsius (CELH) Critical AnalysisAquinox Pharmaceuticals (AQXP) versus Celsius (CELH) Critical Analysis
www.americanbankingnews.com - January 26 at 1:30 PM
Aquinox to Host Analyst and Investor Event in New York CityAquinox to Host Analyst and Investor Event in New York City
finance.yahoo.com - January 26 at 9:08 AM

SEC Filings

Aquinox Pharmaceuticals (NASDAQ:AQXP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aquinox Pharmaceuticals (NASDAQ:AQXP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aquinox Pharmaceuticals (NASDAQ AQXP) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.